1. Hunter NL, O’Callaghan KM, Califf RM. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA. 2015;314(23):2499–500.
2. Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929–39.
3. UCSF. Patient Preference Workshop. Advancing use of patient preference information as scientific evidence in medical product evaluation. 2018. https://pharm.ucsf.edu/cersi/pp-workshop. Accessed 15 Nov 2018.
4. US FDA. Patient preference information: voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. 2016. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf. Accessed 15 Nov 2018.
5. Craig BM, Lancsar E, Mühlbacher AC, Brown DS, Ostermann J. Health preference research: an overview. Patient. 2017;10(4):507–10.